Literature DB >> 22819011

Pre-mRNA splicing in disease and therapeutics.

Ravi K Singh1, Thomas A Cooper.   

Abstract

In metazoans, alternative splicing of genes is essential for regulating gene expression and contributing to functional complexity. Computational predictions, comparative genomics, and transcriptome profiling of normal and diseased tissues indicate that an unexpectedly high fraction of diseases are caused by mutations that alter splicing. Mutations in cis elements cause missplicing of genes that alter gene function and contribute to disease pathology. Mutations of core spliceosomal factors are associated with hematolymphoid neoplasias, retinitis pigmentosa, and microcephalic osteodysplastic primordial dwarfism type 1 (MOPD1). Mutations in the trans regulatory factors that control alternative splicing are associated with autism spectrum disorder, amyotrophic lateral sclerosis (ALS), and various cancers. In addition to discussing the disorders caused by these mutations, this review summarizes therapeutic approaches that have emerged to correct splicing of individual genes or target the splicing machinery.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819011      PMCID: PMC3411911          DOI: 10.1016/j.molmed.2012.06.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  120 in total

1.  The U2AF35-related protein Urp contacts the 3' splice site to promote U12-type intron splicing and the second step of U2-type intron splicing.

Authors:  Haihong Shen; Xuexiu Zheng; Stephan Luecke; Michael R Green
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

2.  SnapShot: The splicing regulatory machinery.

Authors:  Mathieu Gabut; Sidharth Chaudhry; Benjamin J Blencowe
Journal:  Cell       Date:  2008-04-04       Impact factor: 41.582

Review 3.  Functional consequences of developmentally regulated alternative splicing.

Authors:  Auinash Kalsotra; Thomas A Cooper
Journal:  Nat Rev Genet       Date:  2011-09-16       Impact factor: 53.242

Review 4.  RNA-binding proteins with prion-like domains in ALS and FTLD-U.

Authors:  Aaron D Gitler; James Shorter
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

Review 5.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

6.  Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells.

Authors:  Guotai Xu; Cai Zhang; Jian Zhang
Journal:  Mol Med Rep       Date:  2009 Sep-Oct       Impact factor: 2.952

7.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities.

Authors:  Yoshiharu Mizui; Takashi Sakai; Masao Iwata; Toshimitsu Uenaka; Kiyoshi Okamoto; Hajime Shimizu; Takao Yamori; Kentaro Yoshimatsu; Makoto Asada
Journal:  J Antibiot (Tokyo)       Date:  2004-03       Impact factor: 2.649

8.  Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Authors:  Yoshihiko Kotake; Koji Sagane; Takashi Owa; Yuko Mimori-Kiyosue; Hajime Shimizu; Mai Uesugi; Yasushi Ishihama; Masao Iwata; Yoshiharu Mizui
Journal:  Nat Chem Biol       Date:  2007-07-22       Impact factor: 15.040

Review 9.  Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Authors:  Annemieke Aartsma-Rus; Ivo Fokkema; Jan Verschuuren; Ieke Ginjaar; Judith van Deutekom; Gert-Jan van Ommen; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

10.  Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism.

Authors:  Christa Lese Martin; Jacqueline A Duvall; Yesim Ilkin; Jason S Simon; M Gladys Arreaza; Kristin Wilkes; Ana Alvarez-Retuerto; Amy Whichello; Cynthia M Powell; Kathleen Rao; Edwin Cook; Daniel H Geschwind
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-10-05       Impact factor: 3.568

View more
  204 in total

1.  Alternative pre-mRNA splicing of Toll-like receptor signaling components in peripheral blood mononuclear cells from patients with ARDS.

Authors:  Rachel Z Blumhagen; Brenna R Hedin; Kenneth C Malcolm; Ellen L Burnham; Marc Moss; Edward Abraham; Tristan J Huie; Jerry A Nick; Tasha E Fingerlin; Scott Alper
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

Review 2.  Diverse regulation of 3' splice site usage.

Authors:  Muhammad Sohail; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2015-09-14       Impact factor: 9.261

Review 3.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

4.  Evolutionary emergence of a novel splice variant with an opposite effect on the cell cycle.

Authors:  Muhammad Sohail; Jiuyong Xie
Journal:  Mol Cell Biol       Date:  2015-04-13       Impact factor: 4.272

Review 5.  The alternative heart: impact of alternative splicing in heart disease.

Authors:  Enrique Lara-Pezzi; Jesús Gómez-Salinero; Alberto Gatto; Pablo García-Pavía
Journal:  J Cardiovasc Transl Res       Date:  2013-06-18       Impact factor: 4.132

6.  Experimental assessment of splicing variants using expression minigenes and comparison with in silico predictions.

Authors:  Neeraj Sharma; Patrick R Sosnay; Anabela S Ramalho; Christopher Douville; Arianna Franca; Laura B Gottschalk; Jeenah Park; Melissa Lee; Briana Vecchio-Pagan; Karen S Raraigh; Margarida D Amaral; Rachel Karchin; Garry R Cutting
Journal:  Hum Mutat       Date:  2014-09-10       Impact factor: 4.878

Review 7.  A day in the life of the spliceosome.

Authors:  A Gregory Matera; Zefeng Wang
Journal:  Nat Rev Mol Cell Biol       Date:  2014-02       Impact factor: 94.444

8.  In vitro analysis of splice site mutations in the CLCN1 gene using the minigene assay.

Authors:  Gianna Ulzi; Valeria A Sansone; Francesca Magri; Stefania Corti; Nereo Bresolin; Giacomo P Comi; Sabrina Lucchiari
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

9.  Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells.

Authors:  Huan-Huan Wei; Yuanlong Liu; Yang Wang; Qianyun Lu; Xuerong Yang; Jiefu Li; Zefeng Wang
Journal:  J Vis Exp       Date:  2017-04-26       Impact factor: 1.355

Review 10.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.